12:00 AM
 | 
Feb 11, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Mycamine micafungin regulatory update

Astellas said in its 3Q12 earnings ending Dec. 31, 2012, that FDA accepted for review and granted Priority Review to an sNDA for antifungal drug Mycamine micafungin to...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >